Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04225026 · ClinicalTrials.gov registry record · Phase 2
Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer
A Phase 2 study, sponsored by Galera Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT04225026 is a Phase 2 study that was terminated before completion, run by Galera Therapeutics. The registered enrollment target is 39 participants.
The verdict
NCT04225026, a Phase 2 study, was terminated before completion, sponsored by Galera Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
GTI-4419-203 will be an open-label, multi-center study to evaluate GC4419 (avasopasem manganese) administered intravenous (IV) for the reduction of radiation induced esophagitis in subjects receiving chemoradiotherapy for unresectable Stage 3A/3B or post-operative Stage 2B Non-Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) treatable with chemoradiotherapy.
Interventions
- DRUG GC4419 (avasopasem manganese)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2019-12-19 |
| Est. Completion | 2022-03-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04225026
The ClinicalTrials.gov registry entry for NCT04225026 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galera Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GC4419 (avasopasem manganese) is the first listed.
NCT04225026 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04225026 about?
NCT04225026 is a clinical study titled "Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer". GTI-4419-203 will be an open-label, multi-center study to evaluate GC4419 (avasopasem manganese) administered intravenous (IV) for the reduction of radiation induced esophagitis in subjects receiving chemoradiotherapy for unresectable Stage 3A/3B or post-operative Stage 2B Non-Small Cell Lung Cancer...
What is the current status of trial NCT04225026?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2019-12-19. Estimated completion is 2022-03-27.
What interventions are being tested in trial NCT04225026?
The interventions under investigation include: GC4419 (avasopasem manganese) (DRUG).
Who is sponsoring clinical trial NCT04225026?
This trial is sponsored by Galera Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.